



VIJAYA DIAGNOSTIC CENTRE

November 8, 2021

To
Listing Department,
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza,
Bandra Kurla Complex, Bandra (E),
MUMBAI -400 051
Company Code No. VIJAYA

To
The Corporate Relations Department
BSE LIMITED
Phiroz Jeejeebhoy Towers,
25th floor, Dalal Street,
MUMBAI -400 001
Company Code No. 543350

Dear Sirs,

Sub: Intimation of Press Release.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the "Press Release" as mentioned below;

"Vijaya Diagnostic Centre Limited posts strong performance in H1FY22 with Revenue growth of 43% YoY and PAT growth of 114% YoY"

Please take the information on record.

Thanking you,

Yours faithfully,

For Vijaya Diagnostic Centre Limited

Anusha Kanumuru
Company Secretary





Press Release

Vijaya Diagnostic Centre Limited posts strong performance in H1FY22 with Revenue growth of 43% YoY and PAT growth of 114% YoY

Hyderabad, India, November 8, 2021 - Vijaya Diagnostic Centre Limited (NSE: VIJAYA, BSE: 543350) one of the India's leading integrated diagnostic chain has announced its Financial Results for the quarter and half year ended 30th September 2021.

Consolidated Financial Performance:

Particulars (Rs. Mn)	Q2FY22	Q2FY21	YoY	H1FY22	H1FY21	YoY
Revenue from Operations	1,127	1,131	0%	2,354	1,649	43%
EBITDA	511	513	0%	1,080	651	66%
EBITDA Margin (%)	45.4%	45.3%		45.9%	39.5%	
Profit after Tax	277	264	5%	607	283	114%

Performance Highlights H1FY22:

- Revenue from Operations increased by 43% YoY to Rs. 2,354 Mn
- Non-COVID revenue grew by 56% YoY from Rs. 1,326 Mn in H1FY21 to Rs. 2,064 Mn in H1FY22 while COVID revenue (RT-PCR & Antibody tests) declined by 10% YoY to Rs. 290 Mn
- Revenue from B2C segment stood at 93%
- EBITDA stood at Rs. 1,080 Mn, an increase of 66% over corresponding previous period; EBITDA margin for the first half was 45.9%
- PAT increased by 114% YoY to Rs. 607 Mn vs. Rs. 283 Mn in the corresponding previous period
- 5 new diagnostic centres opened during the first half of FY22. The total number of diagnostic centres stands at 85 as on 30th September 2021

Performance Highlights Q2FY22:

- Revenue from Operations came-in at Rs. 1,127 Mn vs. Rs. 1,131 Mn in Q2FY21
- Non-COVID revenue up by 22% YoY to Rs. 1,043 Mn and COVID revenue (RT-PCR & Antibody tests) declined 70% YoY to Rs. 84 Mn
- EBITDA stood at Rs. 511 Mn vs. Rs. 513 Mn in the corresponding previous quarter. EBITDA margin for the quarter was 45.4%
- PAT increased by 5% YoY to Rs. 277 Mn



VIJAYA DIAGNOSTIC CENTRE

Commenting on the performance Ms. Suprita Reddy, CEO said, “We would like to thank the Investors for their great support in making our IPO successful. It has been a long and humble journey to see Vijaya grow as the most trusted and reputed integrated diagnostic chain. Vijaya’s hub and spoke model itself is a unique and tested model creating more meaningful presence & offerings to its customers.

Our core value is to provide reliable and accurate diagnostic services to our customers, at affordable prices, in a customer-centric manner. Our approach along with brand’s recognition for quality diagnostic services, results in high brand recall leading to over 90% of revenue from walk-in customers. We continue to deliver superior patient experience by introducing new patient centric, technology-enabled initiatives.

In the first half of current fiscal, we have opened 5 new centres to service our customers. Our operating revenue stood at Rs. 2,354 Mn in H1FY22; a growth of 43% YoY and EBITDA at Rs. 1,080 Mn with a growth of 66% YoY. We have seen a strong growth in our non-COVID business during this period.

Our strategy is to deepen our presence in core geographies and focus on under-penetrated markets by opening diagnostic centres through owned & franchisee model. We continue our endeavor to service the customers by enhancing laboratory capacity and tests by adding latest technologies. For this we continuously invest in technology, manpower and centre expansions which helps us accelerate our growth further in the coming years.”

About Vijaya Diagnostic Centre Limited (VDCL)

Vijaya Diagnostic Centre Limited (VDCL), is the largest integrated diagnostic chain having dominant presence in South India. Vijaya provides one-stop solution for pathology and radiology testing services to customers through extensive operational network, which consists of 85 diagnostic centres and 11 reference laboratories across 14 cities and towns in the states of Telangana and Andhra Pradesh and in the National Capital Region and Kolkata. The Company offers comprehensive range of diagnostic services from Basic pathology to high-end radiology.

Safe Harbor Statement

This document may contain forward-looking statements about the Company, which are based on the beliefs, opinions and expectations of the Company’s management as the date of this press release and the companies do not assume any obligation to update their forward looking statements if those beliefs, opinions, expectations, or other circumstances should change, these statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. Consequently, readers should not place any undue reliance on such forward-looking statements.

For more Information, please contact:

Mr. Krishna Kiran

Investor Relations

Vijaya Diagnostic Centre Limited

Phone: +91 90597 00749

Email: ir@vijayadiagnostic.in /

krishnakiran@vijayadiagnostic.in

Ms. Neha Shroff

Orient Capital (a division of Link Group)

Phone: +91 77380 73466

Email: neha.shroff@linkintime.co.in